# 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

> **NCT00240435** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 491 (—)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DEVICE:** 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- **DEVICE:** 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler

## Key facts

- **NCT ID:** NCT00240435
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2003-12
- **Final completion:** —
- **Target enrollment:** 491 (—)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240435, "12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00240435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*